GlassScriptPhysician profile
Irina I Kaplan
NPI 1942382718
$6,766.75
in general payments reported to CMS, 2019-2025
37 companies · $888 in 2025
The $888 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $629 · 2020: $675 · 2021: $1,014 · 2022: $1,224 · 2023: $1,119 · 2024: $1,218 · 2025: $888.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,225.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,363.47 | 2021-2025 | |
| Novo Nordisk INC | $1,085.00 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Glaxosmithkline, LLC. | $1,016.31 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $532.51 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $515.49 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astellas Pharma US INC | $301.28 | 2019-2024 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $222.45 | 2020-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $159.54 | 2019-2022 | |
| Abbott Laboratories | $159.13 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Merck Sharp & Dohme LLC | $157.05 | 2019-2021 | |
| Amgen INC. | $136.72 | 2019-2025 | Repatha, Otezla, Repatha |
| Sumitomo Pharma America, INC. | $111.06 | 2023-2025 | Gemtesa |
| Allergan, INC. | $80.41 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $73.09 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $64.33 | 2020-2021 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Irina Kaplan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.